| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
26047 |
| Drug |
Retifanlimab |
| Brand |
Zynyz® |
| Indication |
Retifanlimab (Zynyz®) is indicated in combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal. |
| Rapid review commissioned |
19/09/2026 |
| Rapid review completed |
15/10/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of retifanlimab (Zynyz®) for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE |
15/10/2026 |
